Dalla-Volta S, Scorzelli L, Razzolini R
Am Heart J. 1985 Mar;109(3 Pt 2):682-4. doi: 10.1016/0002-8703(85)90681-7.
The activity of molsidomine, a new antianginal drug, was investigated in 33 patients treated for 3 months with doses of 2 mg, three or four times daily. Exertional angina was present before treatment in 16 patients, spontaneous angina in 5, and mixed angina in twelve. Thirty patients completed the study, and three retired because of side effects. A reduction in the number of attacks of more than 75% in comparison to the pretreatment period was obtained in 20 cases, a diminution between 50% and 75% in 6, and a reduction below 50% in 6. Satisfactory increases in the duration (from 6 minutes 25 seconds to 11 minutes 40 seconds) and maximum load (89.6 to 139.3 W) were obtained in 80% of the cases of effort angina. A dramatic and statistically significant reduction of attacks was observed in the first 48 hours in 8 of 11 patients with spontaneous angina. Side effects were predominantly gastrointestinal and caused the interruption of treatment in 10% of the cases. Molsidomine seems to be a very promising drug for the treatment of effort and spontaneous angina.
对一种新型抗心绞痛药物吗多明的活性进行了研究，33例患者接受了为期3个月的治疗，剂量为每日2毫克，每日三次或四次。治疗前，16例患者患有劳力性心绞痛，5例患有自发性心绞痛，12例患有混合性心绞痛。30例患者完成了研究，3例因副作用退出。与治疗前期相比，20例患者发作次数减少超过75%，6例减少50%至75%，6例减少低于50%。80%的劳力性心绞痛患者在持续时间（从6分25秒增至11分40秒）和最大负荷（从89.6瓦增至139.3瓦）方面有令人满意的增加。11例自发性心绞痛患者中有8例在最初48小时内发作显著减少且具有统计学意义。副作用主要是胃肠道方面的，10%的病例因此中断治疗。吗多明似乎是一种治疗劳力性和自发性心绞痛非常有前景的药物。
